Pioglitazone
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Pioglitazone: From Type 2 Diabetes Mellitus to Opsismodysplasia
One-Sentence Summary
Pioglitazone is an oral insulin-sensitizing drug (a PPAR-gamma agonist) originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for Opsismodysplasia (score 99.59%), but there are 0 clinical trials and 0 publications directly supporting this prediction. It is a graph-based prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 |
| US Market Status | Cancelled only (no currently valid licenses in the data compiled) |
| Number of NDAs | 6 authorizations in total (1 NDA, 5 ANDAs), all cancelled |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, pioglitazone is a PPAR-gamma agonist (thiazolidinedione class), its efficacy in type 2 diabetes is established, and its main effects are insulin sensitization and adipose tissue modulation.
Opsismodysplasia is a rare skeletal dysplasia caused by mutations in INPPL1 (SHIP2, a regulator of the PI3K pathway). Pioglitazone has no established mechanistic connection to this pathway, so any link is speculative. The high TxGNN score reflects graph-based association rather than independent biological or clinical evidence.
Other top-ranked predictions show the same pattern:
- Stiff person syndrome (classic and focal variants, score 99.50%): a theoretical anti-inflammatory/immunomodulatory rationale, with identical scores suggesting a shared graph neighborhood rather than independent evidence.
- Localized lipodystrophies (scores 99.18%–99.30%): PPAR-gamma-driven adipogenesis makes a biological link plausible, but these are local tissue processes with no supporting data for systemic pioglitazone.
- Thiamine-responsive dysfunction syndrome (99.48%) and pancreatic agenesis (99.18%): no clear mechanistic link. In pancreatic agenesis, insulin sensitizers depend on endogenous insulin and would not address the core deficit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for opsismodysplasia.
(For the ninth-ranked prediction, pancreatic agenesis, seven publications were retrieved, but they concern PPAR agonists in type 2 diabetes or prediabetes and are indirect, not relevant to that disease.)
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA021073 | Actos (Takeda Pharmaceuticals America, Inc.) | Tablet | Cancelled |
| ANDA200268 | Pioglitazone Hydrochloride (A-S Medication Solutions) | Tablet | Cancelled |
| ANDA207806 | Pioglitazone (Solco Healthcare LLC) | Tablet | Cancelled |
| ANDA202467 | Pioglitazone (Macleods Pharmaceuticals Limited) | Tablet | Cancelled |
| ANDA077210 | Pioglitazone (Bryant Ranch Prepack) | Tablet | Cancelled |
All six authorizations in the data compiled are listed as cancelled. Indication text was not available.
Safety Considerations
- Contraindications flagged in the knowledge graph (not label text): kidney disease, liver disease, gallbladder disease, congestive heart failure, adrenocortical insufficiency/Addison disease, thymus gland disease, infectious disease, and a large group of pituitary and gonadal deficiency conditions (hypopituitarism, growth hormone deficiency, hypogonadotropic hypogonadism, Kallmann syndrome, Sheehan syndrome, among others).
- Drug Interactions: 100 interactions were found. Examples among the entries reviewed:
- Moderate: abiraterone, acetazolamide, hydrochlorothiazide, hydrocortisone, epinephrine, phenylephrine, pseudoephedrine, salbutamol, formoterol, alpelisib, ethanol, abametapir (topical), aloe vera leaf
- Minor: nifedipine, ethinylestradiol, lipoic acid, topical corticosteroids (hydrocortisone, alclometasone, amcinonide), aminoglutethimide
Please refer to the package insert for label warnings, as these were not available in the data compiled.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a graph-based score. There are no clinical trials or publications for opsismodysplasia, no plausible mechanistic link to INPPL1/SHIP2 biology, and all US licenses are cancelled. Evidence level is L5.
To proceed, the following is needed:
- Mechanism of action data (MOA) and a clear mechanistic hypothesis linking PPAR-gamma agonism to the INPPL1/PI3K pathway
- Preclinical evidence (cell or animal models of opsismodysplasia)
- FDA package insert warnings and contraindications (a blocking gap for safety screening)
- Review of the cancelled licensure status and the current availability of the drug
- Consideration of better-supported alternatives among the other predictions (for example, the lipodystrophy indications), which would still require supporting data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.